PedAM
Pediatric Disease Annotations & Medicines
| Disease | hyperglycemia |
| Phenotype | C0011849|diabetes mellitus |
| Sentences | 78 |
| PubMedID- 23594031 | Aim: the purpose of this study is to evaluate continuous glucose monitoring (cgm) in predicting diabetes mellitus in children with incident hyperglycemia (ih) and negativity for some insular autoantibodies. |
| PubMedID- 22238392 | Context: dapagliflozin, a selective sodium-glucose cotransporter 2 (sglt2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (t2dm) by increasing urinary glucose excretion, and weight loss is a consistent associated finding. |
| PubMedID- 26167540 | hyperglycemia in diabetes mellitus causes oxidative stress and pericyte depletion from the microvasculature of the brain thus leading to the blood-brain barrier (bbb) disruption. |
| PubMedID- 23116444 | The term diabetic cardiomyopathy refers to a state of cardiac dysfunction independent of associated coronary artery disease that arises within weeks of hyperglycemia (hg) leading to longer term diabetes mellitus (dm) [1]. |
| PubMedID- 22128218 | It has been shown that the hyperglycemia associated with diabetes mellitus results in the activation of neutrophils(51) and that this activation contributes to an increase in oxidative stress that is partly responsible for diabetes complications. |
| PubMedID- 22260979 | Although hyperglycemia associated with diabetes mellitus is well known to enhance ros production in vascular endothelial cells, the effects of either acute or chronic high glucose environments on neurons and glial cells remain unclear. |
| PubMedID- 25927597 | In recent years, selective sglt2 inhibitors have been developed and are now in clinical use for the treatment of hyperglycemia in patients with type 2 diabetes mellitus [19]. |
| PubMedID- 21886908 | The purpose of the current study was to assess whether type 2 diabetes mellitus-induced hyperglycemia has an effect on the lipid profile and release of oxidative stress markers and inflammatory mediators in patients with non alcoholic fatty liver disease and normal liver function tests which may in turn lead to enhancing the pathogenicity of this liver disease. |
| PubMedID- 24465132 | When contraindications to its use exist or patients cannot tolerate it due to adverse effects, clinicians have a variety of other classes of agents to treat hyperglycemia associated with type 2 diabetes mellitus. |
| PubMedID- 26528798 | Skeletal muscle is the principal site for postprandial glucose utilization and augmenting the rate of glucose utilization in this tissue may help to control hyperglycemia associated with diabetes mellitus. |
| PubMedID- 26345606 | Persistent hyperglycemia in patients with diabetes mellitus is said to be associated with various complications. |
| PubMedID- 24516103 | Dipeptidyl peptidase-4 inhibitors prevent the degradation of incretin hormones and reduce postprandial hyperglycemia in patients with type 2 diabetes mellitus. |
| PubMedID- 25767499 | Moreover, hyperglycemia in diabetes mellitus can induce hippocampal blood capillary injury, leading to regional ischemia and elevated bad expression levels[2324]. |
| PubMedID- 23576884 | Background: the purpose of this paper is to review the efficacy, safety, and tolerability of linagliptin in the management of hyperglycemia in adults with type 2 diabetes mellitus. |
| PubMedID- 25651730 | Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus. |
| PubMedID- 22211582 | Efficacy of protamine zinc recombinant human insulin for controlling hyperglycemia in dogs with diabetes mellitus. |
| PubMedID- 24250607 | Several drugs such as sulfonylureas and biguanides are presently available to reduce hyperglycemia in diabetes mellitus. |
| PubMedID- 23220949 | Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. |
| PubMedID- 22111038 | It is well established that chronic hyperglycemia in patients with type 2 diabetes mellitus causes progressive deterioration of β-cell function. |
| PubMedID- 22683753 | hyperglycemia in association with diabetes mellitus makes esrd patients resistant to hcy-lowering therapy. |
| PubMedID- 25759411 | Proper keratinocyte migration and proliferation are the crucial steps during reepithelialization, and these steps may be impaired in diabetes mellitus (dm) due to hyperglycemia and chronic inflammation in wound site. |
| PubMedID- 22837722 | Metformin is a biguanide drug that is broadly used in clinical practice to prevent hyperglycemia in patients with diabetes mellitus. |
| PubMedID- 23250800 | Our aim was to determine if increased nitric oxide generation by l-arginine infusion would reverse this deleterious response to clamped hyperglycemia in women with type 1 diabetes mellitus. |
| PubMedID- 26024569 | Purpose: although newer agents (dipeptidyl peptidase [dpp]-4 inhibitors and glucagon-like peptide [glp]-1 receptor agonists) are available for the treatment of hyperglycemia in patients with type 2 diabetes mellitus (t2dm), the impact of the availability of these agents on the use of second-generation sulfonylureas (sus) is unknown. |
| PubMedID- 23315305 | The clinical management of hyperglycemia in patients with type 2 diabetes mellitus (t2dm) is guided not only by published treatment algorithms, but also by consideration of recent evidence and through consultation with colleagues and experts. |
| PubMedID- 21931813 | Also increasing in incidence is type ii diabetes mellitus (t2d), associated with hyperglycemia, insulin-resistance, and hyperlipidemia [3], [6], [7]. |
| PubMedID- 22489155 | diabetes mellitus patients with long-term hyperglycemia produce more ofr due to increased glucose autoxidation and protein saccharification, which weakens oxidation resistance and initiates oxidation stress [22]. |
| PubMedID- 24348462 | Overt diabetes mellitus – with hyperglycemia and severe insulin deficiency as prominent features – can be considered a disorder of domestication in that affected cats would die without treatment. |
| PubMedID- 24858947 | hyperglycemia resulting from type 2 diabetes mellitus (t2dm) is the main cause of diabetic complications such as retinopathy and neuropathy. |
| PubMedID- 22196774 | His laboratory blood values showed a non-regulated diabetes mellitus with hyperglycemia of 32 mmol/l, white blood cell count of 18 × 109/l with 81.6% polymorphonuclear cells (pmns), elevated c-reactive protein (crp), hemoglobin, sodium and creatinine. |
| PubMedID- 21217061 | hyperglycemia in diabetes mellitus promotes oxidative stress in endothelial cells, which contributes to development of cardiovascular diseases. |
| PubMedID- 24717767 | Abnormal regulation of glucagon secretion has been implicated in the development of hyperglycemia in patients with type 2 diabetes mellitus [16], and a recent study in animal models indicated that a reduction in glucagon action can have profound effects on mitigating hyperglycemia even in the presence of severe hypoinsulinemia [17]. |
| PubMedID- 25536610 | Patients with diabetes mellitus or other causes of hyperglycemia were excluded, as pleural fluid glucose has been reported to be sensitive to serum glucose fluctuations. |
| PubMedID- 23231438 | In clinical trials, both exenatide formulations reduced hyperglycemia in patients with type 2 diabetes mellitus (t2dm) and were associated with weight loss. |
| PubMedID- 26253538 | Secondly, we sought to investigate the effect of glp-1 modulation on myocardial function in the setting of hyperglycemia in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 21307777 | Aim: hyperglycemia in diabetes mellitus (dm) may be one of the most important factors responsible for the development of oxidative stress, which promotes the main complications in dm patients. |
| PubMedID- 21713092 | The three major metabolic abnormalities that contribute to hyperglycemia in diabetes mellitus are defective glucose-induced insulin secretion, increased hepatic glucose output and inability of insulin to stimulate glucose uptake in the peripheral target tissues. |
| PubMedID- 26379785 | Chronic hyperglycemia in diabetes mellitus is known to induce numerous chronic complications including micro- and macrovascular injuries, whose diagnosis is often hampered by silent or minor clinical presentation. |
| PubMedID- 21286019 | Glucocorticoids not only exacerbate hyperglycemia in patients with known diabetes mellitus (dm), but also cause dm in patients without documented hyperglycemia before the initiation of glucocorticoid therapy (2). |
| PubMedID- 23423609 | Nonenzymatic glycation of macromolecules, especially proteins leading to their oxidation is increased in diabetes mellitus due to hyperglycemia and play an important role in associated complications of the disease. |
| PubMedID- 25317173 | Early macrovascular atherosclerosis may play a crucial role in subtle brain atrophy in type 2 diabetes mellitus patients, with chronic hyperglycemia playing a lesser role. |
| PubMedID- 23633864 | The oxidative degradation of fructosamines may contribute to the oxidative stress found in hyperglycemia associated with diabetes mellitus. |
| PubMedID- 22247912 | Although the kidney becomes a victim of hyperglycemia in diabetes mellitus, recent work has shown that the abnormalities of lipid and glucose metabolism in the kidney are similarly important to those in adipose tissue. |
| PubMedID- 22649411 | In hyperglycemia, as with diabetes mellitus and metabolic syndrome, high activity of the krebs cycle due to high substrate availability may increase the h+ gradient over the mitochondrial membrane (figure 2a), leading to inhibition of enzymatic steps mediated by complexes within the electron transport chain, including succinate dehydrogenase (complex ii; figure 2a; brownlee, 2005). |
| PubMedID- 25307034 | Our recommendations include: terminology revision from new-onset diabetes after transplantation to posttransplantation diabetes mellitus (ptdm), exclusion of transient posttransplant hyperglycemia from ptdm diagnosis, expansion of screening strategies (incorporating postprandial glucose and hba1c) and opinion-based guidance regarding pharmacological therapy in light of recent clinical evidence. |
| PubMedID- 23454717 | Non-enzymatic glycation, which refers to the spontaneous binding of reducing sugars to free amino groups, is increased in diabetes mellitus because of hyperglycemia and is amplified by oxidative processes ('glycoxidation'). |
| PubMedID- 23614630 | The position statement on the management of hyperglycemia in patients with type 2 diabetes mellitus issued in 2012 by the american diabetes association and the european association for the study of diabetes contains significant improvements over the 2009 version, including an emphasis on patient-centered care, enhanced strategies for lifestyle modification, a focus on comprehensive cardiovascular risk reduction, and increased pharmacotherapy choices. |
| PubMedID- 24790413 | Basal-bolus insulin therapy is an ideal regimen for improving uncontrolled hyperglycemia in patients with diabetes mellitus.1 prandial premixed insulin therapy (ppt), injected three times a day, is also effective for glycemic control in type 2 diabetics.2–9 further, ppt is convenient for patients, because it requires only a single insulin preparation. |
| PubMedID- 25422773 | Diabetic peripheral neuropathy (dpn) is a well-known microvascular complication of type 2 diabetes mellitus attributed to chronic hyperglycemia, and is defined as the presence of peripheral nerve dysfunction in diabetics after exclusion of other causes3–6. |
| PubMedID- 21030101 | Remission of diabetes mellitus type 2 with severe hyperglycemia after exenatide treatment. |
Page: 1 2